Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Development of Rhenium Radiopharmaceuticals from Coordination Chemistry View Point


Affiliations
1 Department of Chemistry, Ananda Chandra College, Jalpaiguri, West Bengal, Pin-735101, India
2 Department of Chemistry, Jangipur College, Jangipur, Murshidabad, West Bengal, Pin-742213, India
     

   Subscribe/Renew Journal


Favourable nuclear properties of radiorhenium (188Re and 186Re) are of interest in the development of new radiotherapeutic and molecular imaging agents. A fundamental critical component of a radio-metal based radiopharmaceutical is the chelator, the ligand system that binds the radio metal ion in a tight stable coordination complex so that it can be properly directed to a desirable molecular target in vivo. The design of a robust Re conjugate can be achieved through a careful selection of the most stable rhenium cores like [Re≡N]2+ and [Re(CO)3]+ that usually are strongly resistant to hydrolysis by water molecules. The chemistry of rhenium has distinct parallels with its group 7 congener technetium in respect of radiopharmaceutical designing and the resulting species are expected to exhibit similar "in vivo" biological behaviour. The labelling of biologically active molecules to generate affinity of radiorhenium complexes for a specific biological target can be achieved by 'bifunctional approach' or by 'metal fragment' strategies. This review highlights the role of coordination chemistry in the design of rhenium radiopharmaceuticals engineered to selectively target tissue of interest such as cancer cells. A range of rhenium complexes with different ligands with rhenium in different oxidation states are introduced and their potential to be translated to new radiotherapeutic agents discussed.

Keywords

Rhenium, Radiopharmaceuticals, Radionuclide Therapy, Coordination Chemistry.
Subscription Login to verify subscription
User
Notifications
Font Size


Abstract Views: 54

PDF Views: 5




  • Development of Rhenium Radiopharmaceuticals from Coordination Chemistry View Point

Abstract Views: 54  |  PDF Views: 5

Authors

Suman Sengupta
Department of Chemistry, Ananda Chandra College, Jalpaiguri, West Bengal, Pin-735101, India
Bikash Kumar Panda
Department of Chemistry, Jangipur College, Jangipur, Murshidabad, West Bengal, Pin-742213, India

Abstract


Favourable nuclear properties of radiorhenium (188Re and 186Re) are of interest in the development of new radiotherapeutic and molecular imaging agents. A fundamental critical component of a radio-metal based radiopharmaceutical is the chelator, the ligand system that binds the radio metal ion in a tight stable coordination complex so that it can be properly directed to a desirable molecular target in vivo. The design of a robust Re conjugate can be achieved through a careful selection of the most stable rhenium cores like [Re≡N]2+ and [Re(CO)3]+ that usually are strongly resistant to hydrolysis by water molecules. The chemistry of rhenium has distinct parallels with its group 7 congener technetium in respect of radiopharmaceutical designing and the resulting species are expected to exhibit similar "in vivo" biological behaviour. The labelling of biologically active molecules to generate affinity of radiorhenium complexes for a specific biological target can be achieved by 'bifunctional approach' or by 'metal fragment' strategies. This review highlights the role of coordination chemistry in the design of rhenium radiopharmaceuticals engineered to selectively target tissue of interest such as cancer cells. A range of rhenium complexes with different ligands with rhenium in different oxidation states are introduced and their potential to be translated to new radiotherapeutic agents discussed.

Keywords


Rhenium, Radiopharmaceuticals, Radionuclide Therapy, Coordination Chemistry.